Hemolytic Disease

2072 Words9 Pages
The interest in studying Rhesus disease stems from an aspiration to understand blood and its’ components at a cellular level. In order to recognize what factors lead to this disease and what components of the cell can be used as indicators/markers to diagnose it, one must have a general idea of the concepts involved in cellular processes. This paper will focus on the causes of hemolytic disease, including natural and/or surgical & medicinal occurrences that cause isoimmunization; how antigens and antibodies are involved, and the effectiveness of Rh immunoglobulin will also be considered. The nature of Rhesus disease or Rh isoimmunization stems from the Rh factor, which is a protein that may be found on the surface of red blood cells. Carrying this protein means that a person is Rh⁺ whereas a person not carrying the protein is Rh⁻. The Rh status is determined by the mother and the father; if one parent is Rh⁺ and the other is Rh⁻, the baby has at least a 50% chance that it will be Rh⁺. Due to the fact that people are genetically predetermined to either have the Rh factor or not, sometimes there is an occurrence where a woman who is Rh⁻ is pregnant with a child who is Rh⁺. Problems can then arise if the blood from the baby enters the mother’s bloodstream; the Rh⁺ blood from the baby causes the mother’s body to create antibodies against it. These antibodies will then attack any Rh⁺ blood cells. This causes no harm to the mother but can create complications with the baby if the antibodies pass to it and destroy some of its blood cells. This is what is referred to as isoimmunization; it only occurs if the baby’s Rh⁺ blood enters the bloodstream unless a woman becomes sensitized to Rh blood when she received an incompatible ... ... middle of paper ... ...y conquerable disease. Works Cited Arthur, G.R., Foote, G., Page, C., Scott, J.S., Thornton, J.G., Tovey, L.A. 1989. Efficacy and Long Term Effects of Antenatal Prophylaxis with Anti-D Immunoglobulin. British Medical Journal. V. 298 (6689). Pg. 1671-1673. Clinical & Experimental Immunology. 1983. IUSI/WHO Notice: Appropriate Uses of Human Immunoglobulin in Clinical Practice. The Journal of Translational Immunology. V. 52 (2). Pg. 417-422. Holder, W.T., McCord, D.L., and Turner, Ralph J. 1984. Isoimmunization with Anti-U Antibody. Journal of the National Medical Association. V.76 (3). Pg. 277-283. Perinatol, J. 2011. Fetal Intraperitoneal Injection of Immunoglobulin Diminishes Alloimmune Hemolysis. Journal of Perinatology. V. 31. Pg. 289-292. Whitehouse, W.L. 1968. Rhesus Isoimmunization and Therapeutic Abortion. British Medical Journal. V.2 (5659). Pg. 759-760.

More about Hemolytic Disease

Open Document